QIAGEN N.V. announced the debut of QIAsymphony Connect, the next generation of QIAGEN's widely adopted automated nucleic acid purification platform, at the 2025 AMP (Ass Association for Molecular Pathology) annual meeting from November 11-15 in Boston. The first public introduction of QIAsymphonyConnect builds on more than 3,000 cumulative placements at the end of 2024 of the first-generation version, with the new generation designed to support liquid biopsy applications with enhanced speed, sample traceability and digital connectivity for labs. Alongside QIAsymphony Connect.
Seamless connectivity: Integrates with LIMS and QIAsphere, QIAGEN's cloud-based platform for remote monitoring and workflow optimization. Enhanced operational efficiency: Supports greater scalability and integration across laboratory processes. QIAsymphony Connect has been made available to selected customers through an early access program ahead of full commercial release in mid-2026, while the current version of QIAsymphony will remain available for purchase as well during the transition.
QIAGEN will showcase advancements across its Sample to Insight workflows, including early-access data and developments from two major precision oncology partnerships. A joint workshop with Element Biosciences on November 12 will feature early-access data from a study led and presented by Dr. Pinar Uysal-Onganer, an associate professor at the University of Westminster, demonstrating an efficient, scalable, comprehensive genomic profiling workflow for characterizing breast cancer FFPE samples using the QIAseq xHYB Trinity CGP on the Element Biosciences Trinity technology, together with CLC Genomics Workbench and QCI Interpret. Commercial launch is anticipated in early 2026.
Data from the collaboration with Myriad Genetics Inc. will also be presented at AMP. However, they involve uncertainties and risks. These risks include, but are not limited to: challenges in managing a successful CEO transition and successor search while providing operational continuity and continued advancement of company strategy; challenges in managing growth and international operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistical dependencies); variability in operating results and the commercial development of products for customers in the Life Sciences and clinical healthcare markets; changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancement; developments or changes in the securities markets and fluctuations in the trading volume and market price of QIAGEN's shares and the successful implementation of the synthetic share repurchase; QIAGEN's ability to successfully close, integrate and achieve the expected benefits of its acquisition of Parse Biosciences, including fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors.
Additional risks and uncertainties are expected to be in the future.
